title: A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks.
abstract: There is no question that incretin-based glucose-lowering medications have proven to be effective glucose-lowering agents. Glucagon-like peptide 1 (GLP-1) receptor agonists demonstrate an efficacy comparable to insulin treatment and appear to do so with significant effects to promote weight loss with minimal hypoglycemia. In addition, there are significant data with dipeptidyl peptidase 4 (DPP-4) inhibitors showing efficacy comparable to sulfonylureas but with weight neutral effects and reduced risk for hypoglycemia. However, over the recent past there have been concerns regarding the long-term consequences of using such therapies, and the issues raised are in regard to the potential of both classes to promote acute pancreatitis, to initiate histological changes suggesting chronic pancreatitis including associated preneoplastic lesions, and potentially, in the long run, pancreatic cancer. Other issues relate to an increase in thyroid cancer. There are clearly conflicting data that have been presented in preclinical studies and in epidemiologic studies. To provide an understanding of both sides of the argument, we provide a discussion of this topic as part of this two-part point-counterpoint narrative. In the point narrative preceding the counterpoint narrative below, Dr. Butler and colleagues provide their opinion and review of the data to date and that we need to reconsider use of incretin-based therapies because of the growing concern of potential risk and based on a clearer understanding of the mechanism of action. In the counterpoint narrative provided below, Dr. Nauck provides a defense of incretin-based therapies and that benefits clearly outweigh any concern of risk.
authors: Diabetes Center, Bad Lauterberg, Bad Lauterberg im Harz, Germany. nauck@diabeteszentrum.de
authors: Michael A
authors: MA
authors: Nauck
mesh_terms: D000818:Animals; D006801:Humans; D054795:Incretins / Q000627:therapeutic use*
chemical_list: D054795:Incretins
references: Diabetes Obes Metab. 2010 Jun;12(6):495-509
references: 20518805
references: J Hepatobiliary Pancreat Sci. 2010 Jan;17(1):24-36
references: 20012328
references: J Clin Invest. 1998 Feb 1;101(3):515-20
references: 9449682
references: Lancet. 2006 Nov 11;368(9548):1696-705
references: 17098089
references: Diab Vasc Dis Res. 2011 Jul;8(3):237-40
references: 21653676
references: Curr Med Res Opin. 2009 Apr;25(4):1019-27
references: 19278373
references: Am J Med. 2011 Jan;124(1 Suppl):S3-18
references: 21194578
references: Endocr Rev. 2012 Apr;33(2):187-215
references: 22323472
references: Lancet. 2008 Oct 4;372(9645):1240-50
references: 18782641
references: Diabetes. 2009 Sep;58(9):2148-61
references: 19509017
references: Diabetologia. 2010 Jan;53(1):153-9
references: 19756486
references: Diabetes Obes Metab. 2007 Sep;9 Suppl 1:23-31
references: 17877544
references: Thyroid. 2011 Feb;21(2):125-34
references: 21186939
references: Diabetes Care. 2013 Jul;36(7):2118-25
references: 23645885
references: Diabetes. 2013 Jul;62(7):2595-604
references: 23524641
references: Diabetes. 2012 May;61(5):1243-9
references: 22338093
references: Int J Clin Pract. 2010 Jun;64(7):984-90
references: 20412332
references: JAMA Intern Med. 2013 Apr 8;173(7):534-9
references: 23440284
references: Diabetes Obes Metab. 2011 Jun;13(6):559-66
references: 21320263
references: Am J Physiol Endocrinol Metab. 2010 Dec;299(6):E1076-86
references: 20923958
references: Diabetologia. 2010 Jan;53(1):1-6
references: 19894028
references: J Clin Endocrinol Metab. 2011 Mar;96(3):853-60
references: 21209033
references: Diabetes. 2009 Jul;58(7):1604-15
references: 19403868
references: Neuroendocrinology. 2011;94(4):291-301
references: 21893952
references: N Engl J Med. 2008 May 1;358(18):1970-1; discussion 1971-2
references: 18456920
references: Diabet Med. 2012 Nov;29(11):1412-8
references: 22416857
references: Diabetes Care. 2010 Nov;33(11):2349-54
references: 20682680
references: Cardiovasc Diabetol. 2011 Mar 16;10:22
references: 21410975
references: Lancet. 2010 Apr 24;375(9724):1447-56
references: 20417856
references: Diabetes. 2010 Jul;59(7):1702-8
references: 20413508
references: Diabetes Obes Metab. 2011 Jan;13(1):7-18
references: 21114598
references: Am J Physiol Endocrinol Metab. 2004 Dec;287(6):E1209-15
references: 15353407
references: Diabetes Obes Metab. 2013 Feb;15(2):112-20
references: 22925682
references: Lancet. 2012 Aug 4;380(9840):475-83
references: 22748821
references: BMC Endocr Disord. 2010 Apr 22;10:7
references: 20412573
references: Endocrinology. 2010 Apr;151(4):1473-86
references: 20203154
references: Diabetol Metab Syndr. 2012 Jul 24;4(1):36
references: 22828124
references: J Clin Endocrinol Metab. 2012 Jan;97(1):121-31
references: 22031513
references: Lancet. 2011 Aug 13;378(9791):607-20
references: 21620466
references: Drugs Today (Barc). 2011 Feb;47(2):99-107
references: 21431099
references: Gastroenterology. 2011 Jul;141(1):150-6
references: 21334333
references: Cardiovasc Diabetol. 2012 Jan 10;11:3
references: 22234149
references: Diabetes. 2012 May;61(5):1250-62
references: 22266668
references: Diabetologia. 2007 Jan;50(1):186-94
references: 17096116
references: Diabetes Obes Metab. 2010 Jun;12(6):485-94
references: 20518804
references: Nature. 2010 Oct 28;467(7319):1114-7
references: 20981102
references: Lancet. 2010 Aug 7;376(9739):431-9
references: 20580422